Literature DB >> 7125632

Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase.

H Kropp, J G Sundelof, R Hajdu, F M Kahan.   

Abstract

Thienamycin (THM), the N-formimidoyl thienamycin derivative MK0787, and related carbapenem antibiotics were metabolized extensively in mice, rats, rabbits, dogs, rhesus monkeys, and chimpanzees. Urinary recovery of THM ranged from a low of 5% in dogs to 58% in rhesus monkeys. Renal clearance rates in dogs and chimpanzees were unusually low, less than glomerular filtration rates. The reduction in clearance of THM and MK0787 from plasma of rats and rabbits after ligation of renal arteries indicate that the kidneys are responsible for 35 and 92%, respectively, of metabolic drug clearance. Degradation was detected only in kidney homogenates. The enzyme activity was membrane bound and sensitive to inhibitors of Zn-metalloenzymes such as EDTA. A renal dipeptidase, dehydropeptidase-I (DHP-I), EC 3.4.13.11, was found to be responsible for the metabolism of the THM-class antibiotics, which exhibit a structural homology to dehydropeptides. A parallel increase in specific activity against THM and the substrate of DHP-I, glycyldehydrophenylalanine, was observed during solubilization and purification of the enzyme from porcine and human renal cortex. DHP-I was found to catalyze the hydrolysis of the beta-lactam ring in THM and MK0787. The products of the enzyme reaction were identical by high-powered liquid chromatography to their respective metabolites found in the urine. Nonbasic N-acylated THM and natural N-acylated carbapenems (epithienamycins and olivanic acids) were degraded 4- to 50-fold faster than THM when exposed to the enzymatic hydrolysis of DHP-I. Good correlations were obtained between the increased susceptibility of the carbapenem antibiotics to DHP-I as measured in the in vitro enzyme assay and the generally lower recoveries of active antibiotic in the urine of test animals. Despite this unusual degree of metabolism localized in the kidney, the plasma half-life of MK0787 and its efficacy against experimental systemic infections in animals remain satisfactory.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7125632      PMCID: PMC183675          DOI: 10.1128/AAC.22.1.62

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  RENAL AMINOPEPTIDASE- AND COPPER-ACTIVATED PEPTIDE HYDROLYSIS.

Authors:  B J CAMPBELL; Y C LIN; M E BIRD
Journal:  J Biol Chem       Date:  1963-11       Impact factor: 5.157

2.  METABOLISM AND ABSORPTION OF 7-(PHENYLACETAMIDO-1-C14)-CEPHALOSPORANIC ACID.

Authors:  H W CULP; F J MARSHALL; R E MCMAHON
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1963

3.  Deacetylcephalosporin C.

Authors:  J D JEFFERY; E P ABRAHAM; G G NEWTON
Journal:  Biochem J       Date:  1961-12       Impact factor: 3.857

4.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

5.  COMPT, a time-sharing program for nonlinear regression analysis of compartmental models of drug distribution.

Authors:  M Pfeffer
Journal:  J Pharmacokinet Biopharm       Date:  1973-04

6.  Physicochemical characterization of renal dipeptidase.

Authors:  D J Armstrong; S K Mukhopadhyay; B J Campbell
Journal:  Biochemistry       Date:  1974-04-09       Impact factor: 3.162

7.  Biological and chemical studies of the cephalosporins.

Authors:  E H Flynn
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1966

8.  Epithienamycins. II. Isolation and structure assignment.

Authors:  P J Cassidy; G Albers-Schonberg; R T Goegelman; T Miller; B Arison; E O Stapley; J Birnbaum
Journal:  J Antibiot (Tokyo)       Date:  1981-06       Impact factor: 2.649

9.  Comparative antibacterial properties in vitro of seven olivanic acid derivatives: MM 4550, MM 13902, MM 17880, MM 22380, MM 22381, MM 22382 and MM 22383.

Authors:  M J Basker; R J Boon; P A Hunter
Journal:  J Antibiot (Tokyo)       Date:  1980-08       Impact factor: 2.649

10.  In vitro activity of N-formimidoyl thienamycin in comparison with cefotaxime, moxalactam, and ceftazidime.

Authors:  L Verbist; J Verhaegen
Journal:  Antimicrob Agents Chemother       Date:  1981-03       Impact factor: 5.191

View more
  78 in total

Review 1.  Comparative pharmacokinetics of the carbapenems: clinical implications.

Authors:  J W Mouton; D J Touzw; A M Horrevorts; A A Vinks
Journal:  Clin Pharmacokinet       Date:  2000-09       Impact factor: 6.447

2.  Pharmacokinetics of meropenem in subjects with various degrees of renal impairment.

Authors:  B A Christensson; I Nilsson-Ehle; M Hutchison; S J Haworth; B Oqvist; S R Norrby
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

3.  In vitro activity of LJC10,627, a new carbapenem antibiotic with high stability to dehydropeptidase I.

Authors:  K Ubukata; M Hikida; M Yoshida; K Nishiki; Y Furukawa; K Tashiro; M Konno; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

4.  Pharmacokinetics of L-749,345, a long-acting carbapenem antibiotic, in primates.

Authors:  J G Sundelof; R Hajdu; C J Gill; R Thompson; H Rosen; H Kropp
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

Review 5.  Characterization of beta-lactamases.

Authors:  K Bush
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

6.  Multicenter in vitro evaluation of SM-7338, a new carbapenem.

Authors:  R N Jones; K E Aldridge; S D Allen; A L Barry; P C Fuchs; E H Gerlach; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

7.  In vitro antibacterial activity and beta-lactamase stability of the new carbapenem SM-7338.

Authors:  Y Sumita; M Inoue; S Mitsuhashi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-10       Impact factor: 3.267

8.  In vitro activity of biapenem (L-627), a new carbapenem, against anaerobes.

Authors:  K E Aldridge; N Morice; D D Schiro
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

9.  Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals.

Authors:  Takahiro Shibayama; Yoko Matsushita; Kenji Kawai; Takashi Hirota; Toshihiko Ikeda; Shogo Kuwahara
Journal:  Antimicrob Agents Chemother       Date:  2006-10-30       Impact factor: 5.191

Review 10.  Meropenem clinical pharmacokinetics.

Authors:  J W Mouton; J N van den Anker
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.